Fármacos biosimilares: un nuevo escenario en las terapias biológicas

Strickland, 2008, Guide to biotechnology, Biotechnology Industry Organization. Gomollon, 2014, Developments in the treatment of inflammatory bowel disease: 2014 overview, Gastroenterol Hepatol., 37, 14 Hernández-García, 2014, Biosimilar drugs, myths and reality, Reumatol Clin., 10, 351, 10.1016/j.reuma.2014.06.009 Zou, 2015, Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma, Cancer Science., 106, 512, 10.1111/cas.12631 Avidor, 2003, Biotechnology and drug discovery: From bench to bedside, Southern Med J., 96, 1174, 10.1097/01.SMJ.0000066654.35645.F7 Mellstedt, 2008, The challenge of biosimilars, Ann Oncol., 19, 411, 10.1093/annonc/mdm345 Agencia Española del Medicamento y Productos Sanitarios. Medicamentos sometidos a seguimiento adicional de su seguridad [consultado 20 Mar 2016]. Disponible en: http://www.aemps.gob.es/vigilancia/medicamentosUsoHumano/seguimiento_adicional.htm. European Medical Agency. Pharmacovigilance legislation [consultado 20 Jun 2015]. Disponible en: http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000491.jsp&mid=WC0b01ac058058f32d. European Medical Agency. Guidelines on pharmacovigilance for medicines for human use [consultado 20 Jun 2015]. Disponible en: http://ec.europa.eu/health/files/eudralex/vol-9/pdf/vol9a_09-2008_en.pdf. Casadevall, 2002, Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin, N Engl J Med., 346, 469, 10.1056/NEJMoa011931 Ebbers, 2011, Today's challenges in pharmacovigilance: What can we learn from epoetins?, Drug Safety., 34, 273, 10.2165/11586350-000000000-00000 Gouw, 2014, Factor VIII products and inhibitor development in severe hemophilia A, N Engl J Med., 368, 231, 10.1056/NEJMoa1208024 IMS Institute for Healthcare Informatics. The global use of medicines: outlookthrough 2017.2013. [consultado 20 Jul 2014]. Disponible:http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/IMS%20Health20Institute/Reports/Global_Use_of_Meds_Outlook_2017/IIHI_Global_Use_of_Meds_Report_2013.pdf. Withdrawal of the marketing authorisation in the European Union of Valtropin [consultado 30 Jul 2014]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2012/08/WC500130939.pdf. Withdrawal of the marketing authorisation in the European Union of Filgastrim ratiopharm [consultado 30 Jul 2014]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2011/07/WC500109157.pdf. Fox, 2012, Debate over details of US biosimilar pathway continues to rage, Nat Biotechnol., 30, 577, 10.1038/nbt0712-577 Pal, 2013, WHO strategy for collecting safety data in public health programmes: Complementing spontaneous reporting systems, Drug Safety., 36, 75, 10.1007/s40264-012-0014-6 Milch, 2006, Voluntary electronic reporting of medical errors and adverse events. An analysis of 92,547 reports from 26 acute care hospitals, J Gen Intern Med., 21, 165 Cullen, 1995, The incident reporting system does not detect adverse drug events: a problem for quality improvement, Jt Comm J Qual Improv., 21, 541 Real Decreto 577/2013, de 26 de julio, por el que se regula la farmacovigilancia de medicamentos de uso humano [consultado 10 Feb 2016]. Disponible en: http://www.boe.es/diario_boe/txt.php?id=BOE-A-2013-8191. Wise, 2009, New approaches to drug safety: A pharmacovigilance tool kit, Nat Rev Drug Discov., 8, 779, 10.1038/nrd3002 Zink, 2009, European biologicals registers: Methodology, selected results and perspectives, Ann Rheum Dis., 68, 1240, 10.1136/ard.2008.091926 Strangfeld, 2011, Detection and evaluation of a drug safety signal concerning pancreatic cancer: Lessons from a joint approach of three European biologics registers, Rheumatology (Oxford)., 50, 146, 10.1093/rheumatology/keq301 Fischer, 2014, Prospective observational cohort studies for studying rare diseases: The European PedNet Haemophilia Registry, Haemophilia., 20, e280, 10.1111/hae.12448 Farmacovigilancia de medicamentos de uso humano. Agencia Española del Medicamento [consultado 10 Mayo 2016]. Disponible en: http://www.aemps.gob.es/vigilancia/medicamentosUsoHumano/home.htm. Lovis, 2008, Traceabiliy in healthcare: crossing boundaries, vol. 47 (Suppl 1), 105 European Commission, health systems and products, pharmaceuticals. Delegated act on the detailed rules for a unique identifier for medicinal products for human use, and its verification. Artículo disponible para consulta pública. Brussels; 2011 [consultado 14 Jul 2015]. Disponible en: http://ec.europa.eu/health/files/counterf_par_trade/safety_2011-11.pdf. Vermeer, 2013, Traceability of Biopharmaceuticals in Spontaneous Reporting Systems: A cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance Databases, Drug Saf., 36, 617, 10.1007/s40264-013-0073-3 European Medicines Agency, Committee for medicinal products for human use (CHMP). Guideline on plasma-derived medicinal products (EMA/CHMP/BWP/706271/2010) [consultado 27 Jul 2011]. Disponible en: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/07/WC500109627.pdf. National Collaborating Centre for Chronic Conditions (UK). Rheumatoid arthritis. NICE Clinical Guidelines, No. 79. London: Royal College of Physicians; 2009.. Datamatrix adopted by French pharmaceutical industry 2011 [consultado 27 Jul 2015]. Disponible en: http://eipg.eu/wpcontent/uploads/2013/11/EIP8-Feb11- P14.pdf. European Federation of Pharmaceutical Industries and Associations (EFPIA). A vision for the coding and identificationof pharmaceutical products in Europe. Version 4.0, January 2008 [consultado 27 Jul 2015]. Disponible en: http://ec.europa.eu/health/files/counterf_par_trade/doc_publ_consult_200803/114_b_efpia_en.pdf. Figueiras, 2006, An educational intervention to improve physician reporting of adverse drug reactions: A cluster-randomized controlled trial, JAMA., 296, 1086, 10.1001/jama.296.9.1086 Ortega, 2008, Efficacy of an adverse drug reaction electronic reporting system integrated into a hospital information system, Ann Pharmacother., 42, 1491, 10.1345/aph.1L130 Bar coding on pharmaceutical packaging cuts costs and improves patient safety [consultado 27 Jul 2015]. Disponible en: www.gs1ie.org/Download_Files/Healthcare_Files/Haemophilia_Treatment_Traceability_Case_Studyv2.pdf. Chen, 2006, Developing a camera-phone-based drug barcode reader and support system, AMIA Annu Symp Proc, 2006, 882 Felson, 2011, American College of Rheumatology/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials, Arthritis Rheum., 63, 573, 10.1002/art.30129 Hyrich, 2007, Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study, Arthritis Rheum., 56, 13, 10.1002/art.22331 Ebbers, 2012, The safety of switching between therapeutic proteins, Expert Opin Biol Ther., 12, 1473, 10.1517/14712598.2012.711308 Schneider, 2012, Setting the stage for biosimilar monoclonal antibodies, Nat Biotechnol., 30, 1179, 10.1038/nbt.2447 Flodmark, 2013, Switching from originator to biosimilar human growth hormone using dialogue team work: Single-center experience from Sweden, Biol Ther., 3, 35, 10.1007/s13554-013-0011-z Van Schouwenburg, 2013, Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis, Nat Rev Rheumatol., 9, 164, 10.1038/nrrheum.2013.4 Scheinberg, 2012, The advent of biosimilar therapies in rheumatology “O brave new world”, Nat Rev Rheumatol., 8, 430, 10.1038/nrrheum.2012.84 Ungar, 2014, The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab, Gut., 63, 1258, 10.1136/gutjnl-2013-305259 Bartelds, 2011, Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up, JAMA., 305, 1460, 10.1001/jama.2011.406 European Medicines Agency. How to prepare and review a summary of product characteristics [consultado 27 Jul 2015]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document _library/scyentific_guideline/2012/06/WC500128686.pdf. The INN crowd. Nature Biotechnology. 2013;31(12):1055 [consultado 12 Oct 2015]. Disponible en: http://www.nature.com/nbt/journal/v31/n12/pdf/nbt.2760.pdf. Vermeer, 2014, Traceability of biologicals: Present challenges in pharmacovigilance, Expert Opin Drug Saf., 14, 63, 10.1517/14740338.2015.972362 Weise, 2012, Ehmann F,Ekman N, Giezen T, et al. Biosimilars: what clinicians should know, Blood., 120, 5111, 10.1182/blood-2012-04-425744 European Medicines Agency: Working parties and other groups [consultado 27 Ene 2016]. Disponible en: http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000102.jsp&mid=WC0b01ac058002d0ec. Guideline on similar biological medicinal products.CHMP/437/04 [consultado 12 Oct 2015]. Disponible en: http://www.ema.europa.eu/docs/en GB/document library/Scientific guideline/2014/10/WC500176768.pdf. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. EMA/CHMP/BWP/247713/2012 [consultado 12 Sept 2015]. Disponible en: http://www.ema.europa.eu/docs/en GB/document library/Scientific guideline/2009/09/WC500003953.pdf. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMEA/CHMP/BMWP/42832/2005 [consultado 19 Jul 2015]. Disponible en: http://www.ema.europa.eu/docs/en GB/document library/Scientific guideline/2015/01/WC500180219.pdf. European Comission. Directive 2010/84/UE, Reg. (UE) 1235/2010 [consultado 12 Ene 2015]. Disponible en: http://ec.europa.eu/health/files/eudralex/vol-1/dir_2010_84/dir_2010_84_en.pdf. European Comission. Healthcare Industries [consultado 13 Ene 2016] Disponible en: http://ec.europa.eu/growth/sectors/healthcare/. Apéndice 1 de la Directriz sobre Buenas Prácticas de Farmacovigilancia (GVP) Módulo VI: Gestión y notificación de reacciones adversas de medicamentos) [consultado 12 Sept 2015]. Disponible en: www.boe.es/buscar/act.php?id=BOE-A-2008-13682.